The ACR is aware of the emerging concerns surrounding access to needed treatments such as #MTX after the recent decision in Dobbs v. Jackson Women’s Health Organization.

or if any initial disruptions are potentially temporary & due to the independent actions of pharmacists trying to figure out what is & isn’t allowed where they practice.

The ACR has assembled a task force of medical & policy experts to determine the best course of action for ensuring our patients keep access to treatments they need.

In the meantime, we are asking members & patients who have experienced challenges accessing #MTX to email advocacy @rheumatology .org with details.

@ACRheum As we closely follow the access situation with MTX, let us remind patients to restrain from fear-based comments on their SM platforms. Let us give pharmacists in each state time to decide the best way to approach this critical issue as we continue to support patient communities.